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WITHIN A FIRST EPISODE PSYCHOSIS NEUROLEPTIC NAIVE 
POPULATION 
 
KIRANPREET KAUR DHALIWAL  
 
ABSTRACT 	
Background: Soft neurological signs (SNS) are subtle, nonspecific neurological 
abnormalities that are present in first episode psychosis (FEP) patients. SNS are 
associated with clinical variables such as poor long term psychosocial functioning, 
executive functioning, and positive and negative symptomology. However, few studies 
have evaluated treatment responsiveness with respect to SNS.  
 
Objective: To investigate whether SNS show: 1.) baseline and longitudinal differences 
between both diagnostic groups (schizophrenia (FEP-SZ), non-schizophrenia FEP-NSZ, 
and healthy controls (HC)) and treatment outcome (week 26 and year 1); 2.) relationships 
to clinical measures; 3.) predictive characteristics of treatment response. 
 
Methods: SNS scores (Neurological Evaluation Scale) were obtained for 312 FEP (236 
FEP-SZ and 76 FEP-NSZ subjects and 169 HC subjects and for subjects classified as 
treatment responsive and non-responsive at week 26 (N=105, N=105) and year 1 (N=101, 
		 vii 
N=97), respectively. Diagnostic group and treatment responsiveness group comparisons 
were assessed with ANCOVA and logistic regression models and both were co-varied for 
age, sex, race, and handedness. Baseline and longitudinal SNS relationships to clinical 
variables were determined using Spearman correlations and repeated measures 
correlations, and both were corrected by False Discovery Rate. Linear mixed effects 
model was utilized to analyze the data longitudinally. 
 
Results: Baseline	cognitive	perceptual	SNS	measures	had	the	greatest	effect	size	differences,	were	predictive	of	group	membership,	and	differentiated	the	two	proband	groups	with	FEP-SZ	having	worse	SNS	scores.		Baseline	cognitive	perceptual	SNS	did	not	significantly	predict	treatment	response	at	week	26	or	year	1,	but	changes	in	cognitive	perceptual	at	week	26	was	predictive	of	treatment	responsiveness	at	week	26	and	year	1.	Longitudinally,	SNS	scores	drop	in	both	FEP	groups	and	treatment	groups.	The	FEP-SZ	group	showed	greater	longitudinal	within	subject	correlations	than	FEP-NSZ.	SNS	scores	were	only	differentiated	between	year	1	outcome	groups	at	week	8.	There	were	greater	longitudinal	within	subject	correlations	for	the	responsive	group.		
 
Conclusion: Our findings indicate that there are baseline group differences and that 
changes in cognitive perceptual SNS scores at week 26 are predictive of treatment 
responsiveness at week 26 and year 1.  
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  INTRODUCTION 	
Schizophrenia (SZ) is a chronic, heterogeneous, and debilitating psychiatric 
disorder that affects 1% of the adult population and represents a major impact on 
morbidity and mortality rates. SZ may be triggered by an array of interconnected genetic, 
developmental, and environmental factors that interfere with normal brain development 
and maturation (Insel, 2010).  Studies have shown that familial and ultra high-risk 
subjects demonstrate a 10% and 35% risk of developing first episode psychosis (FEP), 
respectively (Tandon et al., 2012, Fusar-Poli et al., 2012).  The onset of illness typically 
begins in early adolescence, but is often not recognized or diagnosed until late 
adolescence or early adulthood. Compared to healthy controls (HC), SZ patients 
generally experience more pronounced abnormalities in positive and negative symptoms, 
global assessment of function (GAF), neurocognition, and social impairment (Insel, 
2010).  Despite these phenomenological characteristics, there is no known common SZ 
trigger. Notably, studies of neurocognitive dysfunction as measured by soft neurological 
signs (SNS) have identified significant relationships with GAF, positive and negative 
symptoms, and cognition in high risk for psychosis, FEP schizophrenia (FEP-SZ), and 
chronic SZ populations.  However, a few studies have evaluated these measures 
longitudinally within the FEP-SZ population. Thus, we aim to study a prospective FEP 
population with minimal to no confounding influence of previous neuroleptic usage, 
chronicity, and institutionalization (Keshavan et al., 1998).   
 
Soft Neurological Signs 
	2 
Soft neurological signs are subtle, nonspecific neurological abnormalities that are 
often observed when assessing sensory integration, motor coordination, and motor 
sequencing of complex movements during clinical evaluations (Bachmann et al., 2005, 
Keshavan et al., 2003).  A longitudinal study evaluating the developmental neurobiology 
in children indicated that typically before the age of 18, children have elevated SNS 
scores that gradually decline with motor maturation (Martins et al., 2008). However, 
young adults with neuropsychiatric disorders do not experience this steady decline and 
tended to have persistently elevated SNS (Martins et al., 2008). Moreover, SNS are 
generally present prior to SZ diagnosis and treatment initiation suggesting that SNS are 
an intrinsic feature of SZ (Bachmann et al., 2003; Buchanan and Heinrichs, 1989).  
Previous studies have documented a 50-65% SNS prevalence rate in SZ patients, a 32% 
prevalence rate in first episode psychosis non-schizophrenia (FEP-NSZ) compared to a 
5% prevalence rate in HC subjects (Bombin et al., 2005; Tucker et al., 1975). 
Furthermore, previous studies have shown that SNS are higher in high-risk relatives of 
schizophrenia patients and in the unaffected co-twins of monozygotic twin-pairs 
discordant for schizophrenia than in healthy controls (Bachmann et al., 2014, Torrey et 
al., 1994).  Additionally, Keshavan has previously shown that FEP-SZ patients have 
higher cognitive perceptual SNS scores than either FEP-NSZ or HC (Keshavan et al., 
2003). 
Longitudinal studies evaluating SNS in SZ have demonstrated that SNS scores 
improve over the course of the illness, but do not drop down to levels similar to HCs 
(Mayoral et al., 2012). Previous literature has shown that the chronicity of antipsychotic 
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use can reduce SNS scores (Schröder et al., 1998).  Additionally, SZ patients that have 
both increased SNS and negative/positive symptoms tend to have worse prognosis than 
patients with lower scores.  A prospective study recently showed that subjects with 
prominent negative symptoms had significantly higher SNS scores compared to subjects 
with less negative symptoms (Chan et al., 2015).  Generally, longer durations of 
untreated illnesses (DUI; time from onset of first psychotic symptom to treatment) tend to 
have worse prognosis (Keshavan et al., 2003; Wyatt, 1991) and in a three-year 
prospective longitudinal study of SNS in a FEP population, it was determined that a 
shorter DUI was associated with lower SNS scores (Chen et al., 2005).  Moreover, GAF 
scores, which measure the global social, occupational, and psychological functioning, 
tend to be lower in SZ patients compared to healthy controls (Caletti et al., 2013).  Taken 
together, an objective measure such as SNS could act as a biomarker for identifying FEP 
patients, determining severity of illness, and predicting treatment response.  
 
Treatment Responsiveness Outcome Groups  
The major domains associated with SZ diagnosis include positive symptoms 
(hallucinations, delusions), negative symptoms (paucity of thought, lack of affect), and 
cognitive symptoms (deficits in working memory and attention, poor social functioning) 
(Tamminga, 2008) with positive and negative symptom severity determining remission 
outcome (Andreasen et al. 2005; Kahn et al., 2015). Therefore, studies commonly define 
treatment response has being measured as a 25% reduction in symptomology (Andreasen, 
et al., 2013). Overall, subjects with severe positive and negative symptoms tend to have a 
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poor prognosis compared to those subjects with fewer positive and negative symptoms.  
Additionally, previous studies have shown that SNS scores are associated with 
symptomology, in particular negative symptoms (Chan et al., 2015) and that decreases in 
SNS parallel symptomology remission (Bachmann et al., 2005). Taken together, changes 
in SNS should parallel changes in symptomology.  
 
Specific Aims 
The first aim of this thesis was to evaluate baseline differences in SNS between 
FEP and HCs, as well as between treatment responders and non-responders at week 26 
and year one. The second aim was to determine the relationships between SNS and 
clinical variables at baseline in the FEP and treatment response groups. The third aim 
examined whether baseline or longitudinal changes in SNS could predict treatment 
response at week 26 and year one. The fourth aim evaluated the change in SNS over time 
to determine whether there was a group by time interaction. Lastly, we examined whether 
longitudinal changes in SNS and clinical variables were related to each other.  
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METHODS  
  
Participants 
 The study protocol, consent form, and in the case of minors, assent, with a 
guardian providing informed consent, were reviewed and approved by the IRB at the 
University of Pittsburgh and VA Pittsburgh Healthcare System. The recruitment and 
assessment methods were described previously (Gilbert et al., 2001).  From 1996 to 2004, 
the study population comprised of FEP patients from inpatient and outpatient services of 
the Western Psychiatric Institute and Clinic, Pittsburgh. Patients were included in the 
study if their diagnosis met DMS-IV criteria for psychosis and were previously untreated.  
Patient exclusion criteria included subjects with significant head injury, no substance 
abuse or dependence, neurological/medical illness, prior neuroleptic exposure, or mental 
retardation (Keshavan et al., 2003).  HC were recruited from local neighborhoods and 
communities and exclusion criteria included a current or previous axis I disorder, history 
of neurological disorders, prior exposure to psychotropic medication, first-degree relative 
history of schizophrenia or mood disorders, or mental retardation (Keshavan et al., 2003).  
 
Clinical Assessment 
 Neurological evaluations were obtained at multiple time points (baseline, week 4, 
week 8, week 26, year 1, year 2, and year 4) by trained clinicians.  Baseline evaluations 
in the FEP population were performed prior to the patient receiving antipsychotic 
medications. Trained clinicians performed a modified Buchanan-Heinrich neurological 
evaluation scale (NES) that yields repetitive motor and cognitive perceptual subscale 
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scores (Heinrich and Buchanan, 1988, Keshavan et al., 2003).  Criteria utilized for the 
creation of a modified SNS scale has been previously described by Keshavan et al., 2003.  
Keshavan, performed a factor analysis which identified two factors 1) repetitive motor 
factor (finger edge palm, fist-ring, alternating fist palm, and rapid alternating movements) 
and 2) cognitive perceptual  (audiovisual integration, face hand test, and verbal memory), 
which differentiated FEP-SZ and FEP-NSZ from HCs.  
Global functioning measures were obtained from the global assessment scale 
(GAS), for participants in proband groups. All groups were accessed for perseverative 
error, which is measured by obtaining the percentage of perseverative errors made on the 
Wisconsin Card Sort Test (WCST) (Robinson et al., 1980).  Clinical measures including 
positive and negative symptoms were obtained from the Scale for the Assessment of 
Positive Symptoms (SAPS) and Negative Symptoms (SANS), respectively (Andreasen et 
al., 1990).  DUI was also determined from the onset of first psychotic symptom to the 
onset of treatment.  
 
Participant Quality Assurance and Characterization   
 The original sample included 701 subjects, of which 220 participants were 
excluded due to being offspring, siblings, or a parent of a high-risk participant, or were 
diagnosed with a non-psychosis DSM-IV diagnosis. Patients with missing predominant 
hand information were excluded (Bachmann et al., 2005). Following exclusion, there 
were 312 FEP subjects and 169 HC subjects.  Additionally, FEP subjects were divided 
into two groups: FEP-SZ (participants with a psychosis and schizophrenic, 
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schizophreniform, schizoaffective, or other SZ diagnosis, n=236) and FEP-NSZ 
(participants with a non-schizophrenia diagnosis, such as Bipolar 1 disorder with 
psychosis, major depressive affective disorder with psychosis, or another psychosis 
diagnosis, n=76) groups based on their DSM-IV diagnosis.  
 
Treatment Response Outcome Groups 
A subset of the FEP subjects, who had both baseline and follow-up (week 26 or 
year 1) SANS and SAPS scores were included and characterized into treatment 
responsive and non-responsive groups.  Past literature has defined treatment response 
groups as those subjects who experienced a minimum of 20% reduction in total 
symptoms from baseline (Kahn et al., 2015) and we utilized a slightly stricter criteria of 
25% reduction of total symptoms (average of SANS and SAPS scores) from baseline as 
treatment responsive.  Average symptomatology changes were calculated by dividing 
follow-up scores by baseline scores. Participants who had greater than a 25% reduction in 
symptoms from baseline were characterized as treatment responsive and those who had 
less than 25% reduction from baseline were characterized as treatment non-responsive. 
As a result, subjects were classified as treatment responsive and non-responsive at week 
26 (N=105, N=105) and year 1 (N=101, N=97), respectively.  
 
Data Cleaning and Imputation  
From the 481 subjects assessed at baseline, 43 subjects were missing baseline 
cognitive perceptual and repetitive motor SNS scores (32 FEP-SZ (13.5%,), 7 FEP-NSZ 
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(9%), and 4 HC (2%)).  Multiple imputations (n=100) were performed within the three 
groups at baseline, taking the average score for each SNS measure that was then used for 
subjects with missing data, and executed using the Amelia II package in R (Honaker, 
King, Blackwell, 2015).  
Missing baseline socioeconomic status was imputed for both missing mother (19 
FEP-SZ (8%), 13 FEP-NSZ (17%), and 3 HC (2%)) and father (42 FEP-SZ (18%), 10 
FEP-NSZ (13%), and 6 HC (4%)) data utilizing the Amelia II package.  Once multiple 
imputations (n=100) were performed, an average of socioeconomic status score was 
generated for missing mother and father, respectively.  Afterwards, mother and father’s 
socioeconomic status score was averaged to create an overall score per participant. 
 
SNS Change Score  
 For subjects that had SNS measures at baseline and either week 26 or year 1, the 
change in SNS was calculated.  For each respective SNS measure, baseline data was 
subtracted from a follow-up SNS measure to create a change score for both week 26 and 
year 1. 
 
Statistical Analyses  
All statistical analyses were performed using the R statistical analysis software 
(version 3.3.3, https://www.r-project.org/). See below for further details. 
 
Demographics    
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Demographics of FEP-NSZ, FEP-SZ, HC, treatment response, and treatment non-
response participants were analyzed with independent chi-squared tests or one-way 
analysis of variance (ANOVA).  For the diagnostic groups, clinical demographics and 
number of antipsychotics data was calculated for each time point (baseline, week 4, week 
8, week 26, year 1, year 2, and year 4). For the treatment response groups, clinical 
demographics were calculated at week 26 and year one. Age, sex, and antipsychotic 
usage were assessed at each additional time point.  
 
Baseline Analysis  
1. Group Contrasts and Effect Sizes   
SNS, cognitive, and clinical measures were tested for normal distribution utilizing 
visual inspection of histograms. For non-normal data, non-parametic approaches (such as 
Quasi-Poisson regression) were implemented. 
 Pair-wise contrasts (FEP-NSZ to HC, FEP-SZ to HC, FEP-NSZ to FEP- SZ) were 
run for SNS measures (cognitive perceptual and repetitive motor) between the three 
groups utilizing a linear model for simple regression. Effect sizes (Cohen’s d coefficient) 
were calculated for each group comparison. The data was adjusted for sex, race, parental 
socioeconomic status, and handedness prior to calculations. All p-values were adjusted 
for multiple comparisons using False Discovery Rate (FDR) correction. A similar 
approach was utilized for comparisons between responsive and non-responsive groups at 
week 26 and year 1.  
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2. Logistic Regression 
 Logistic regression analysis was used to examine a baseline multivariate 
prediction model with group classification as the dependent variable and cognitive 
perceptual and repetitive motor SNS measures as the predictor variables. Predictor 
variables for the week 26 and year 1 treatment groups includes cognitive perceptual and 
repetitive motor SNS measures, change from baseline to week 26 cognitive perceptual 
and repetitive motor scores, and duration of illness. Additionally, for year 1 predictor 
variables, the change from baseline to year 1 cognitive perceptual and repetitive motor 
scores were also utilized.  Odds ratios and upper and lower confidence intervals at 95% 
were calculated for each model. All data was co-varied for age of consent, sex, race, and 
handedness. 
  
3. Partial Correlations  
 Relationships between clinical (positive symptoms, negative symptoms), 
cognitive (perseverative error), and GAF were performed using Spearman correlations	
and the data was adjusted for sex, race, parental socioeconomic status, and handedness 
prior to calculations. P values were adjusted using FDR correction for multiple 
comparisons within each proband group, as well as treatment response groups at both 
week 26 and year 1.  
 
Clinical Longitudinal Analysis  
1. Linear Mixed Effects Model  
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 The lme4 R package was used to analyze a group (FEP and HC) by time point 
interaction effect for cognitive perceptual and repetitive motor SNS measures. The fixed 
effects (race, age of consent, handedness, and sex) and the random effect (individual 
differences across age at time point) were accounted for within the linear mixed effects 
model. Pairwise contrasts for FEP-NSZ to HC, FEP-SZ to HC, and FEP-NSZ to FEP-SZ 
were also run. All p values were adjusted for multiple comparisons using FDR correction. 
 Within the treatment response groups at week 26 and year 1, the linear mixed 
effects model approach utilized was similar to the one described above. Calculations for 
week 26 treatment group included time points up to week 26, while year one calculations 
included time points up to year 1.  P values were adjusted for multiple comparisons using 
the FDR correction. 
 
2. Within Subject Measure Correlations  
Repeated measure correlations calculate a common regression slope, which 
represents the association between individuals within a group. This methodology 
addresses the assumption of independence violation when calculating correlations at 
multiple time points (Bakdash and Marusich, 2017). Calculation of the repeated measures 
correlation coefficient was determined using rmcorr package in R and used to determine 
within subject associations between each SNS measure and clinical variables for 
diagnostic and treatment groups. All data was adjusted for age, race, sex, and handedness. 
P values were adjusted for multiple comparisons using FDR correction.   
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  RESULTS  	
Baseline	and	Longitudinal	Demographics	
Social-demographic characteristics of probands and HC at multiple time points 
within the study, as well as baseline clinical measures are summarized in Table 1.  At 
baseline, there were statistically significant differences of sex and averaged parental 
social economic status between the three groups. Additionally, between the FEP-SZ and 
FEP-NSZ, there were baseline significant differences observed in both positive and 
negative symptoms. There was no statistical difference between the proband groups for 
duration of illness.  Additionally, there were significant differences between the proband 
for antipsychotic usage at all time points.  
TABLE	1.	Demographic	data	for	FEP-NSZ,	FEP-SZ,	and	HC’s.	Note:	FEP-NSZ=	first	episode	psychosis	non-schizophrenia,	FEP-SZ=first	episode	psychosis	schizophrenia,	HC=healthy	controls.	AA=African American, OT=other, CA=	
Caucasian. SNS=soft neurologic signs)	
BASE
LINE 
Demographic Features FEP-NSZ 
(n=76) 
FEP-
SZ 
(n=236) 
HC 
(n=169) 
 (X^2,F) p value 
 Age at Time Point Mean (sd) 23.2 (7.4) 24.9 
(8.2) 
24.3 
(6.9) 
1.53 0.218 
 Sex (Female/Male)* 29/47 80/156 84/85 10.4 0.006 
 Race (AA /OT/CA) 18/5/53 90/18/1
28 
50/10/1
09 
7.98 0.092 
 Handedness 
(Right/Mixed/Left) 
68/5/3 210/8/1
8 
156/4/9 4.38 0.357 
 Average Parental SES Mean 
(sd)* 
43.6 (12.66) 39.2 
(12.5) 
42.7 
(10.9) 
6.61 0.001 
 Negative Symptoms Mean 
(SD)* 
1.75 (0.4) 2.13 
(0.6) 
      ----- 30.8 <0.001 
 Positive symptoms Mean 
(SD)* 
0.55 (0.4) 0.85 
(0.5) 
      ----- 22.6 <0.001 
 Average Positive/Negative 
Score Mean (sd)* 
1.15 (0.4) 1.49 
(0.4) 
      ----- 41.3 <0.001 
 Duration of illness from 1st 
symptom Mean (sd)^ 
119.9 
(228.1) 
147.1 (273.1)  ----       0.60 0.441 
 Antipsychotics (1/2/NA)* 4/0/72 17/2/21
7 
      ----- 14.6 0.006 
	13 
WEEK 
4 
 FEP_NSZ 
(n=27) 
FEP_S
Z 
(n=94) 
HC 
(n=2) 
  
 Age at Time Point Mean (sd) 23.3 (7.5) 25.3 
(8.2) 
24.6 
 (6.0) 
0.97 0.382 
 Sex (Female/Male) 12/22 36/78 29/40 2.05 0.359 
 Antipsychotics (1/2/3/NA)* 20/0/0/14 77/3/2/
32 
      ----- 93.2 <0.001 
WEEK 
8 
 FEP_NSZ 
(n=28) 
FEP_S
Z 
(n=64) 
HC 
(n=65) 
  
 Age at Time Point Mean (sd) 24.2 (7.9) 22.9 
(5.6) 
23.5 
(6.4) 
0.50 0.609 
 Sex (Female/Male) 14/18 33/50 39/32 3.64 0.162 
 Antipsychotics (1/2/NA)* 19/1/12 54/2/27       ----- 79.7 <0.001 
WEEK 
26 
 FEP_NSZ 
(n=48) 
FEP_S
Z 
(n=138
) 
HC 
(n=66) 
  
 Age at Time Point Mean (sd) 24.2 (7.6) 24.9 
(7.6) 
24.2 
(6.2) 
0.50 0.624 
 Sex (Female/Male) 22/32 61/110 65/68 5.38 0.068 
 Antipsychotics (1/2/NA)* 21/3/30 112/6/5
3 
      ----- 152 <0.001 
YEAR 
1 
 FEP_NSZ 
(n=43) 
FEP_S
Z 
(n=127
) 
HC 
(n=127) 
  
 Age at Time Point Mean (sd) 24.7 (8.1) 25.6 
(7.8) 
24.9 
(6.2) 
0.52 0.593 
 Sex (Female/Male)* 19/34 51/108 71/72 10.1 0.006 
 Antipsychotics (1/2/3/NA)* 21/1/1/30 92/4/2/
61 
----- 130 <0.001 
YEAR 
2 
 FEP_NSZ 
(n=14) 
FEP_S
Z 
(n=54) 
HC 
(n=36) 
  
 Age at Time Point Mean (sd) 26.0 (6.4) 29.5 
(8.7) 
28.3 
(6.5) 
1.33 0.268 
 Sex (Female/Male) 7/8 24/41 21/22 1.64 0.44 
 Antipsychotics (1/2/3/NA)* 4/1/0/10 34/6/2/
23 
----- 46.3 <0.001 
YEAR 
4 
 FEP_NSZ 
(n=8) 
FEP_S
Z 
(n=32) 
HC 
(n=14) 
  
 Age at Time Point Mean (sd) 27.8 (6.5) 30.9 
(9.1) 
31.4 
 (5.9) 
0.688 0.506 
 Sex (Female/Male) 4/5 13/22 11/8 2.15 0.342 
 Antipsychotics (1/2/3/NA)* 1/1/0/7 18/5/2/
10 
      ----- 28.1 <0.001 
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Treatment Response Demographics  
 Baseline social-demographic, clinical, and cognitive characteristics of patients 
characterized as responsive or non-responsive at week 26 or year 1 within the study were 
summarized in Table 2.  For week 26 treatment groups, there was no statistically 
significant difference between responsive and non-responsive patients for baseline sex, 
age, averaged parental socioeconomic status, cognitive perceptual scores, repetitive 
motor scores, or antipsychotic usage. However, there was a trending difference between 
the groups for race (p<0.1) and a significant difference between the groups for duration 
of illness (p<0.022). Patients in the responder group tended to have a shorter duration of 
illness compared to the non-responders.  At year 1, there were no significant differences 
between mean age, duration of illness, baseline cognitive perceptual scores, baseline 
repetitive motor scores, and antipsychotic usage. There were significant differences for 
sex (p<0.05), race (p<0.01), handedness (p<0.01), and average parental socioeconomic 
status (p<0.05).  
TABLE 2: Baseline demographics for response and non-response at week 26 and year 1. 
Note: AA=African American, OT=other, CA=	Caucasian, SES= socioeconomic status, 
SNS=soft neurological signs)  
Baseline	Demographics	for	subjects	assigned	Response	or	Non-
Response	at	Week	26	or	Year	1	
	
	 	 WEEK	26		 Year	1	
	 	 No 
Response 
(n=105) 
Response 
n=(105) 
(X^2
,F) 
p-
val
ue 
 No 
Response 
n=(97) 
Response 
n=(101) 
(X^2
,F) 
p-
value 
Age Mean  (sd)  23.9 
(7.3) 
24.2 (7.8) 0.052 0.82
1 
 25.2 (7.8) 23.4 (8.0) 2.5 0.115 
Sex (Female/Male)  34/71	 41/64	 3.99	 0.1
36	
	 33/64	 33/68	 6.5	 0.039	
Race (AA/OT/CA)  43/6/5
6	
23/9/73	 9.06	 0.0
60	
	 42/5/50	 20/11/7
0	
14.3	 0.007	
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Handedness 
(Right/Mixed/Left
) 
 95/3/7 88/7/10	 7.15	 0.1
28	
	 88/1/8	 83/9/9	 14.9	 0.005	
Average Parental 
SES Mean (sd) 
 39.6 
(12.5) 
42.35	
(13.2)	
2.47	 0.1
18	
	 38.6	
(11.9)	
42.59	
(13.7)	
4.84	 0.029	
Duration of illness 
Mean (sd) 
 140.1 
(211.5) 
79.08	
(166.4)	
5.34	 0.0
22	
	 130.3	
(195.8)	
85.40	
(179.6)	
2.79	 0.097	
Baseline Cognitive 
Perceptual Mean 
(sd) 
 0.57 
(0.5) 
0.567	
(0.5)	
<0.0
01	
0.9
76	
	 0.51	(0.5)	 0.55	
(0.5)	
0.34
8	
0.556	
Baseline 
Repetitive Motor 
Mean (sd) 
 0.52 
(0.4) 
0.59	
(0.5)	
1.29
0	
0.2
57	
	 0.49	(0.4)	 0.59	
(0.5)	
2.12	 0.147	
Baseline Average 
SNS Mean (sd) 
 0.54 
(0.3) 
0.543	
(0.3)	
0.01
7	
0.8
97	
	 0.50	(0.3)	 0.54	
(0.3)	
1.18	 0.280	
Antipsychotics  
(1/2/NA) 
 5/1/99 4/0/101	 1.31
0	
0.8
59	
	 33/69/5	 4/0/97	 1.42	 0.840	
 
Baseline Analysis  
1. Group Contrasts and Effect Sizes   
 Diagnostic group classification comparisons showed significant SNS differences 
between group contrasts.  FEP-SZ group showed the greatest significant increases for 
cognitive perceptual (p<0.001, Cohen’s D=1) and repetitive motor (p<0.001, Cohen’s 
D=0.56).  FEP-NSZ group compared to HC also showed statistically significant increases 
in cognitive perceptual and repetitive motor tasks, with moderate effect sizes of 0.65 and 
0.51, respectively.  For the FEP-SZ to FEP-NSZ group comparison, there were 
statistically significant (p<0.05) results for both cognitive perceptual and repetitive 
motor, with effect sizes of -0.44 and -0.23, respectively. Figure 1 illustrates these SNS 
differences for group comparisons.  
	16 
 
FIGURE 1: Baseline effect sizes of SNS measures based on group comparisons with 
95% confidence intervals. Note: Data was adjusted for sex, age of consent, race, and 
handedness.  
 
Contrasts of baseline cognitive perceptual SNS measures between responsive and 
non-responsive treatment groups at week 26 did not show statistically significant 
differences.  There was a trending significance (p<0.1) between the responders and non-
responders for repetitive motor SNS measures with mild effect sizes (Cohen’s D=0.81). 
At year 1, there were significant differences (p<0.05) between the two groups for 
repetitive motor, but no statistical difference for cognitive perceptual SNS measures.  
Figure 2 illustrates the SNS treatment response and non-response group comparisons.  
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FIGURE 2: Baseline cognitive perceptual and repetitive motor SNS measures by non-
response and response treatment groups at week 26 and year 1. Data was adjusted for sex, 
race, age of consent, and handedness.  
 
2. Logistic Regression 
Evaluations of the logistic regression model for group predictions are illustrated 
in Figure 3.  Within the FEP-SZ to HC group, there were significant differences for both 
baseline cognitive perceptual and repetitive motor scores (p<0.001).  Calculation of the 
odds ratio between these two group was significant and illustrates that the odds of being 
in the FEP-SZ group is 17.4 more than being in the HC group for subjects with worse 
cognitive perceptual scores at baseline. The repetitive motor odds ratio was also 
significant, but not as strong as the cognitive perceptual. Within the FEP-NSZ to HC 
comparisons, both SNS measures were significant, with cognitive perceptual measures 
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having a stronger effect than repetitive motor. The odds ratio estimation shows that the 
odds of the FEP-NSZ group are 8.2 more than the HC group to have worse cognitive 
perceptual SNS measures.  Comparisons between the FEP-SZ and FEP-NSZ groups 
showed significant results for cognitive perceptual measures, but not repetitive motor or 
duration of illness. Evaluation of the odds ratio between these groups illustrates small 
odds of 2.7 more for being in the FEP-SZ group over the FEP-NSZ group, with the FEP-
SZ group having worse baseline cognitive perceptual measures (Supplemental Table 1).  
 
FIGURE 3: Odds ratio of group differences for baseline cognitive perceptual, repetitive 
motor, and duration of illness scores. Note: Data was co-varied for age, sex, race, and 
handedness. FEP-NSZ= first episode psychosis non-schizophrenia, FEP-SZ= first 
episode schizophrenia, HC=healthy controls, DUI= Duration of Untreated Illness. 
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  Evaluations of the logistic regression model for treatment groups predictions are 
illustrated in Figure 4.  These results demonstrate that baseline cognitive perceptual 
(OR=2.6-2.8) and the change in week 26 cognitive perceptual from baseline was 
predictive (OR = 4.5-4.6) of being a responder than being a non-responder for both week 
26 and year 1 treatment response groups.  These findings were all significant, except for 
baseline cognitive perceptual was not significant for year 1. Further data analysis details 
are shown in Supplemental Table 2.  
 
FIGURE 4: Odds Ratio of non-response and response at week 26 and year 1 for baseline 
cognitive perceptual, repetitive motor, duration of untreated illness, and changes in 
cognitive perceptual and repetitive motor at week 26 and year 1. Data was co-varied for 
age, sex, race, and handedness. (DUI= Duration of Untreated Illness, 
COGPER=cognitive perceptual, REPMOT= repetitive motor, R= Response, NR = Non-
response) 
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3. Correlations 
3a. Diagnostic Groups  
 Evaluation of baseline cognitive perceptual measures correlations to clinical 
measures reveals more significant correlations within the FEP-SZ group than the FEP-
NSZ group. After adjusting for multiple comparisons, baseline cognitive perceptual 
scores were significantly positively correlated to negative symptoms, average of positive 
and negative symptoms, and perseverative error in the FEP-SZ group (p<0.01).  In the 
FEP-SZ, global assessment scores were negatively trending (p<0.1) with cognitive 
perceptual measures. There were no correlations between duration of untreated illness 
and cognitive perceptual measures. There were no significant correlations between SNS 
measures in the FEP-NSZ group to negative symptoms, positive symptoms, average 
positive and negative symptoms, perseverative error, global assessment, or duration of 
untreated illness. Overall, greater baseline cognitive perceptual SNS scores were 
associated with worse symptomatology and perseverative error in the FEP-SZ group 
compared to the FEP-NSZ group.  
 Within the FEP-SZ group, baseline repetitive motor scores were not significantly 
correlated with negative symptoms, positive symptoms, average positive and negative 
symptoms, perseverative error, or duration of untreated illness.  Within the FEP-NSZ 
group, baseline repetitive motor scores were not significantly correlated with negative 
symptoms, positive symptoms, average positive and negative symptoms, perseverative 
error, or GAS scores. However, within this group, repetitive motor score to duration of 
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illness correlation displayed trending significance (p<0.1).  Overall, repetitive motor 
scores were not correlated to other clinical measures.   
TABLE 3: Baseline Correlations for Cognitive Perceptual and Repetitive Motor to 
clinical measures, cognitive measures, and duration of illness in FEP-SZ and FEP-NSZ. 
Note: Data was adjusted for age, sex, race, and handedness. FEP-NSZ=	first	episode	psychosis	non-schizophrenia,	FEP-SZ=first	episode	psychosis	schizophrenia,	GAS=Global	Assessment	Scale,	DUI=	Duration	of	untreated	illness. 
Baseline	FEP-SZ	v	FEP-NSZ	Group	Correlations	
	 	 FEP_SZ	 FEP_NSZ	 	
	 r	value	 p	value	 Adjusted		
p	value	
r	value		 p	
value	
Adjusted	
p	value		
COGNITIVE	PERCEPTUAL	 	 	 	 	 	 	
NEGATIVE	SYMPTOMS	 0.176	 0.007	 0.032*	 0.149	 0.199	 0.943	
POSITIVE	SYMPTOMS	 0.082	 0.212	 0.317	 -0.097	 0.406	 0.943	
AVERAGE	POS/NEG	
SYMPTOMS	
0.173	 0.008	 0.032*	 0.039	 0.740	 0.943	
PERSEVERATIVE	ERROR	 0.322	 <0.001	 0.002*	 0.179	 0.256	 0.943	
GAS	 -0.139	 0.034	 0.100	 0.020	 0.861	 0.943	
DUI	 0.027	 0.678	 0.740	 0.008	 0.943	 0.943	
REPETITIVE	MOTOR	 	 	 	 	 	 	
NEGATIVE	SYMPTOMS	 0.075	 0.253	 0.331	 0.079	 0.499	 0.943	
POSITIVE	SYMPTOMS	 0.118	 0.070	 0.119	 -0.116	 0.319	 0.943	
AVERAGE	POS/NEG	
SYMPTOMS	
0.120	 0.066	 0.119	 0.012	 0.918	 0.943	
PERSEVERATIVE	ERROR	 0.162	 0.060	 0.119	 0.077	 0.625	 0.943	
GAS	 -0.071	 0.276	 	0.331	 		-0.015	 					0.896	 0.943	
DUI	 <-
0.001	
0.994	 0.994	 0.317	 0.006	 0.074	
 
3b. Treatment Responsive Groups  
 Baseline correlations for treatment responsiveness at week 26 revealed that within 
the responsive group there are no significant correlations between symptomology, 
perseverative error, or GAS scores and cognitive perceptual SNS scores. However, within 
the non-responsive group, there were significant positive correlations between cognitive 
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perceptual and symptomology, and perseverative error scores and negative correlations 
between cognitive perceptual and GAS. There was no correlation between duration of 
illness and cognitive perceptual for either group. Symptomology, GAS and duration of 
illness were not correlated to repetitive motor SNS scores for either group. Within the 
responsive group, executive function is correlated with repetitive motor SNS scores, but 
was not shown for the non-responsive group.  Refer to Table 4 for additional results.  
 
TABLE 4: Baseline Correlations for Subjects Assigned Response and Non-Response at 
Week 26. Note: Data was adjusted for age, sex, race, and handedness. GAS= Global 
Assessment Scale, DUI= Duration of Untreated Illness. 
Baseline	Correlations	for	Subjects	Assigned	Response	v	Non-Response	at	Week	26	
		 	 Response		 Non-Response		
	 r	value	 p	value	 Adjusted	
p	value	
r	
value		
p	
value	
Adjusted	
p	value		
Cognitive	Perceptual		 	 	 	 	 	 	
NEGATIVE	SYMPTOMS	 0.205	 0.036	 0.158	 0.293	 0.003	 0.015	
POSITIVE	SYMPTOMS	 0.116	 0.240	 0.361	 0.271	 0.005	 0.020	
AVERAGE	POS/NEG			
SYMPTOMS	
0.187	 0.057	 0.158	 0.325	 <0.00
1	
0.009	
PERSEVERATIVE	ERROR	 0.248	 0.043	 0.158	 0.329	 0.010	 0.024	
GAS	 -0.079	 0.424	 0.508	 -
0.264	
0.007	 0.020	
DUI	 0.041	 0.678	 0.678	 0.004	 0.971	 0.971	
Repetitive	Motor		 	 	 	 	 	 	
NEGATIVE	SYMPTOMS	 0.176	 0.072	 0.158	 0.027	 0.783	 0.855	
POSITIVE	SYMPTOMS	 0.149	 0.129	 0.221	 0.084	 0.394	 0.473	
AVERAGE	POS/NEG	
SYMPTOMS	
0.172	 0.0790	 0.158	 0.095	 0.333	 0.473	
PERSEVERATIVE	ERROR	 0.408	 <0.001	 0.007*	 0.114	 0.381	 0.473	
GAS	 -0.091	 0.358	 0.477	 -
0.109	
0.268	 0.473	
DUI	 0.0513	 0.605	 0.660	 0.104	 0.295	 0.473	
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 Baseline correlations for treatment responsiveness at year 1 revealed that between 
cognitive perceptual and negative symptoms there is a statistically significant (p<0.05) 
positive correlation in the non-responsive group, but none with positive symptoms, 
perseverative error, GAS, or DUI. There are positive correlation between perseverative 
error and both cognitive perceptual and repetitive motor SNS measures in the responsive 
group, but no correlation to the other clinical measures.  Overall, fewer relationships are 
observed between clinical and SNS measures within treatment outcome year 1 compared 
to week 26. Refer to Table 5 for additional correlation results. 
TABLE 5: Baseline Correlations for Subjects Assigned Response and Non-Response at 
Year 1. Data was adjusted for age, sex, race, and handedness. (GAS= Global Assessment 
Scale, DUI= duration of untreated illness) 
Baseline	Correlations	for	Subjects	Assigned	Response	v	Non-Response	at	Year	1		
	 	 Response		 Non-Response		
	 r	value	 p	value	 Adjuste
d	p	
value	
r	value		 p	
value	
Adjusted	
p	value		
COGNITIVE	PERCEPTUAL	 	 	 	 	 	 	
NEGATIVE	SYMPTOMS	 0.052	 0.607	 0.728	 0.339	 <0.00
1	
0.009*	
POSITIVE	SYMPTOMS	 0.198	 0.047	 0.188	 0.097	 0.342	 0.684	
AVERAGE	POS/NEG	
SYMPTOMS	
0.144	 0.151	 0.261	 0.267	 0.009	 0.051	
PERSEVERATIVE	ERROR	 0.429	 <0.001	 0.006*	 0.218	 0.100	 0.299	
GAS	 -0.114	 0.255	 0.340	 -0.188	 0.070	 0.281	
DUI	 -0.042	 0.676	 0.738	 0.049	 0.636	 0.949	
REPETITIVE	MOTOR	 	 	 	 	 	 	
NEGATIVE	SYMPTOMS	 0.136	 0.174	 0.261	 -0.007	 0.949	 0.949	
POSITIVE	SYMPTOMS	 0.161	 0.107	 0.257	 -0.008	 0.935	 0.949	
AVERAGE	POS/NEG	
SYMPTOMS	
0.177	 0.077	 0.232	 -
0.0502	
0.624
6	
0.949	
PERSEVERATIVE	ERROR	 0.332	 0.007	 0.042*	 0.031	 0.818	 0.949	
GAS	 -0.137	 0.173	 0.261	 -0.010	 0.920	 0.949	
DUI	 -0.006	 0.956	 0.956	 0.140	 0.173	 0.414	
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Longitudinal Analysis 
1. Linear Mixed Effects Model and Mean Differences for Diagnostic Groups  
 There was a significant group effect between probands and HCs, with FEP-SZ 
having the worst cognitive perceptual SNS scores and FEP-NSZ having moderate SNS 
scores compared to HCs.  There was also a significant age at time point difference 
between the groups (data not shown). However, there was no group by time interaction.  
There were statistically significant cognitive perceptual SNS score differences between 
FEP-SZ and HC at baseline, week 8, week 26, year 1, and year 2 (Figure 5).  Further data 
analysis results are shown in Supplemental Table 3.  For the repetitive motor SNS scores, 
there was a statistically significant time point fixed effect and a significant group effect. 
There was a significant time by group effect for FEP-NSZ to FEP-SZ and FEP-NSZ to 
HC at year 4.  
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FIGURE 5: Cognitive Perceptual SNS measure across multiple time points with 
confidence intervals. Note: FEP-NSZ= first episode psychosis non-schizophrenia, FEP-
SZ= first episode schizophrenia, HC=healthy controls, WK = week, YR = year, 
TIMEPT=Time Point) 
 
2. Linear Mixed Effects Model and Mean Differences for Treatment Outcome  
 Between the non-response and response groups at week 26, there was a 
significant age at time point fixed effect for cognitive perceptual SNS measures (data not 
shown). However, there was no group or group by age at time point interaction observed. 
Evaluation of cognitive perceptual mean differences reveals that at week 26, treatment 
responsiveness differences were trending at week 26 (Figure 6). For repetitive motor, 
there was a significant time point fixed effect, but there was no significant group effect or 
group by time point interaction.  Evaluation of repetitive motor mean differences reveals 
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trending differences at baseline and significant differences at week 8(Supplemental Table 
4).  
 
FIGURE 6: Trajectory of cognitive perceptual SNS measures between week 26 non-
response and response at baseline, week 4, week 8, and week 26 time points with 
confidence intervals. Note: NR_wk26= non-responders at week 26, R_wk26= responders 
at week 26, TIMEPT = time point. 
 
 Between the cognitive perceptual SNS measures for non-response and response 
groups at year 1, there was a significant time point fixed effects and group by time point 
interactions, but there was no group effect (data not shown). Cognitive perceptual mean 
differences reveal statistically significant differences at week 8 (Figure 7).  Evaluation of 
repetitive motor reveals an age at time point fixed effect for repetitive motor SNS 
measures. However, there is no group or group by time point interaction observed. Mean 
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differences indicate significant differences at baseline and week 26 (Supplemental Table 
5).  
FIGURE 7: Baseline cognitive perceptual trajectories across Non-Response and 
Response treatment groups at year 1 with confidence intervals. Note: NR= Non-
Response, R= Response, txyr1 = treatment response at year 1, WK = week, YR= year) 	
4. Within Subject Repeated Measure Correlations 
 Within subject repeated measures correlations were evaluated for all time points 
in FEP-SZ and FEP-NSZ groups. Within the FEP-SZ group, there were significant 
associations between cognitive perceptual SNS scores and perseverative error, global 
assessment functioning, and negative and positive symptoms (p<0.001) with relationships 
ranging from -0.3 to0.3. The perseverative error and positive and negative scores are 
positively associated with cognitive perceptual scores, with decreases in these clinical 
and SNS measures indicating improvements. GAS scores are negatively correlated with 
cognitive perceptual SNS scores. Within the FEP-NSZ group, there were statistically 
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significant positive correlations between cognitive perceptual and negative and positive 
symptoms and significant negative correlations with GAS scores. There was no 
significant correlation between perseverative error and cognitive perceptual.  Repeated 
measures correlations were also calculated for repetitive motor SNS to these clinical 
measures for both groups and results are in Table 6. 	Overall,	cognitive	perceptual	had	more	and	stronger	correlations	to	the	clinical	measures	than	repetitive	motor	scores 
 
TABLE	6:	Repeated	Measures	Correlations	for	Diagnostic	Groups.	Data	was	adjusted	for	age,	sex,	race,	and	handedness.	(FEP=First	Episode	Psychosis,	GAS=Global	assessment	scale)	
Group		 Measure		 r	 p	 p.adj	 CI	lower	 CI	upper	
FEP	Schizophrenia	 COGNITIVE	PERCEPTUAL		
Negative	
Symptoms		
0.200	 <0.001	 <0.001	 0.115	 0.283	
	 Positive	Symptoms		 0.327	 <0.001	 <0.001	 0.246	 0.402	
	 AVERAGE	
SYMPTOMS	
0.324	 <0.001	 <0.001	 0.244	 0.400	
	 Perseverative	
error	
0.275	 <0.001	 <0.001	 0.146	 0.394	
	 GAS	 -0.303	 <0.001	 <0.001	 -0.381	 -0.222	
	 	 REPETITIVE	MOTOR		 	
Negative	
Symptoms		
0.173	 <0.001	 <0.001	 0.087	 0.256	
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	 Positive	Symptoms		 0.158	 <0.001	 0.001	 0.072	 0.242	
	 AVERAGE	
SYMPTOMS		
0.201	 <0.001	 <0.001	 0.116	 0.284	
	 Perseverative	
error		
0.117	 0.087	 0.108	 -0.018	 0.247	
	 GAS	 -0.164	 <0.001	 <0.001	 -0.248	 -0.078	
FEP	Non-
Schizophrenia	
	 COGNITIVE	PERCEPTUAL	 	
	 Negative	
Symptoms		
0.260	 0.001	 0.001	 0.112	 0.396	
	 Positive	Symptoms		 0.204	 0.008	 0.013	 0.054	 0.345	
	 AVERAGE	
SYMPTOMS	
0.262	 0.001	 0.001	 0.115	 0.398	
	 Perseverative	
error			
0.185	 0.135	 0.159	 -0.062	 0.410	
	 GAS	 -0.227	 0.003	 0.005	 -0.366	 -0.078	
	 REPETITIVE	MOTOR		 	
	 NEGATIVE	
SYMPTOMS			
0.037	 0.636	 0.674	 -0.116	 0.187	
	 POSITIVE	
SYMPTOMS	
0.048	 0.531	 0.584	 -0.104	 0.199	
	 AVERAGE	
SYMPTOMS			
0.048	 0.532	 0.584	 -0.104	 0.199	
	 PERSEVERATIVE	
ERROR	
0.061	 0.625	 0.674	 -0.186	 0.300	
	 GAS	 0.021	 0.785	 0.822	 -0.131	 0.172	
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Within subject correlations for response groups at week 26 and year 1 revealed 
significant correlations between cognitive perceptual and all clinical measures with 
relationships ranging from -0.3 to 0.4. Within the non-responsive group at week 26 and 
year 1, there was a significant positive correlation between positive symptoms and 
perseverative error to cognitive perceptual. There were also significant negative 
correlations between GAS and cognitive perceptual measures within the both week 26 
and year 1 non-responsive group. Overall, cognitive perceptual and repetitive motor 
showed stronger relationships to the clinical measures in responsive groups, with 
repetitive motor displaying fewer relationships. Refer to Tables 7 and 8 for additional 
repeated measures correlations for repetitive motor.  
 
TABLE	7:	Repeated	Measures	Correlation	for	Treatment	Response	at	Week	26.	Data	was	adjusted	for	age,	sex,	race,	and	handedness.	(GAS=Global	assessment	scale)	
Group		 Measure		 r	 p	 p.adj	 CI	lower	 CI	upper	
RESPONSE	AT	
WEEK	26	
COGNITVE	PERCEPTUAL		
	 	
NEGATIVE	
SYMPTOMS		
0.295	 <0.001	 <0.001	 0.189	 0.394	
	 POSITIVE	
SYMPTOMS		
0.393	 <0.001	 <0.001	 0.293	 0.484	
	 AVERAGE	
SYMPTOMS		
0.387	 <0.001	 <0.001	 0.287	 0.478	
	 PERSEVERATIVE	
ERROR	
0.288	 0.001	 <0.001	 0.128	 0.434	
	 GAS	 -0.312	 <0.001	 <0.001	 -0.410	 -0.207	
	 REPETITIVE	MOTOR		 	
	 NEGATIVE	
SYMPTOMS		
0.241	 <0.001	 <0.001	 0.132	 0.344	
	 POSITIVE	
SYMPTOMS		
0.181	 0.001	 0.003	 0.070	 0.288	
		 AVERAGE	
SYMPTOMS		
0.235	 <0.001	 <0.001	 0.126	 0.339	
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		 PERSEVERATIVE	
ERROR	
0.205	 0.015	 0.022	 0.040	 0.359	
		 GAS	 -0.140	 0.014	 0.021	 -0.249	 -0.028	
NON-RESPONSE	
AT	WEEK	26	
		
	 COGNITIVE	PERCEPTUAL	 	
NEGATIVE	
SYMPTOMS		
0.086	 0.141	 0.164	 -0.029	 0.199	
POSITIVE	
SYMPTOMS		
0.190	 0.001	 0.002	 0.076	 0.298	
		
		
AVERAGE	
SYMPTOMS		
0.201	 0.001	 0.001	 0.088	 0.309	
PERSEVERATIVE	
ERROR	
0.237	 0.008	 0.013	 0.061	 0.398	
		
		
		
		
		
		
		
		
		
		
		
GAS	 -0.242	 <0.001	 <0.001	 -0.347	 -0.130	
REPETITIVE	MOTOR	
NEGATIVE	
SYMPTOMS		
0.007	 0.906	 0.916	 -0.108	 0.122	
POSITIVE	
SYMPTOMS		
0.105	 0.073	 0.092	 -0.010	 0.218	
AVERAGE	
SYMPTOMS		
0.082	 0.163	 0.185	 -0.034	 0.195	
PERSEVERATIVE	
ERROR	
-0.009	 0.921	 0.921	 -0.187	 0.170	
GAS	 -0.088	 0.133	 0.159	 -0.202	 0.027			
TABLE	8:	Repeated	Measures	Correlations	for	Treatment	Groups	at	Year	1.	Data	was	adjusted	for	age,	sex,	race,	and	handedness.	(GAS=Global	Assessment	Scale)	
Group		 Measure		 r	 p	 p.adj	 CI	lower	 CI	upper	
RESPONSE	AT	
YEAR	1	
		
	 COGNITIVE	PERCEPTUAL		 	
NEGATIVE	
SYMPTOMS		
0.268	 <0.001	 <0.001	 0.161	 0.369	
		 POSITIVE	
SYMPTOMS		
0.403	 <0.001	 <0.001	 0.305	 0.493	
		 AVERAGE	
SYMPTOMS		
0.389	 <0.001	 <0.001	 0.290	 0.480	
		 PERSEVERATIVE	
ERROR	
0.332	 <0.001	 <0.001	 0.174	 0.472	
		 GAS	 -0.338	 <0.001	 <0.001	 -0.434	 -0.235	
	 	 REPETITIVE	MOTOR		 	
		 NEGATIVE	
SYMPTOMS		
0.236	 <0.001	 <0.001	 0.128	 0.339	
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		 POSITIVE	
SYMPTOMS		
0.163	 0.004	 0.007	 0.052	 0.270	
		 AVERAGE	
SYMPTOMS		
0.227	 <0.001	 <0.001	 0.118	 0.330	
		 PERSEVERATIVE	
ERROR	
0.223	 0.008	 0.013	 0.058	 0.376	
		 GAS	 -0.141	 0.013	 0.020	 -0.249	 -0.030	
NON-RESPONSE	
AT	YEAR	1	
		
COGNITIVE	PERCEPTUAL	
NEGATIVE	
SYMPTOMS		
0.070	 0.250	 0.281	 -0.050	 0.188	
		 POSITIVE	
SYMPTOMS		
0.197	 0.001	 0.002	 0.080	 0.309	
		 AVERAGE	
SYMPTOMS		
0.183	 0.002	 0.004	 0.065	 0.296	
		 PERSEVERATIVE	
ERROR	
0.261	 0.005	 0.008	 0.081	 0.424	
		 GAS	 -0.198	 0.001	 0.002	 -0.310	 -0.080	
	 	 REPETITIVE	MOTOR		 	
		 NEGATIVE	
SYMPTOMS		
0.029	 0.637	 0.674	 -0.091	 0.148	
		 POSITIVE	
SYMPTOMS		
0.156	 0.010	 0.016	 0.037	 0.270	
		 AVERAGE	
SYMPTOMS		
0.126	 0.039	 0.053	 0.006	 0.242	
		 PERSEVERATIVE	
ERROR	
0.021	 0.819	 0.847	 -0.163	 0.205	
		 GAS	 -0.129	 0.035	 0.048	 -0.245	 -0.009		 	
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DISCUSSION 
 
Baseline cognitive perceptual SNS measures had the greatest effect size 
differences, were predictive of group membership, differentiated the two proband groups 
with FEP-SZ having worse SNS scores, and were positively associated with negative 
symptoms and perseverative error scores.  Baseline cognitive perceptual SNS did not 
significantly predict treatment response at week 26 or year 1, but changes in cognitive 
perceptual at week 26 was predictive of treatment responsiveness at week 26 and year 1. 
Additionally, baseline cognitive perceptual was positively associated with negative 
symptoms and perseverative error for treatment responsiveness at week 26 and year 1. 
Longitudinally, SNS scores decrease in both FEP groups, with FEP-NSZ dropping to 
similar levels as HCs, but FEP-SZ subjects do not experience such a drastic change and 
remain impaired. Also, FEP-SZ group showed more longitudinal within subject 
correlations between cognitive perceptual SNS to symptom, cognitive, and functional 
measures compared to FEP-NSZ. With regards to treatment response at week 26 and year 
1, cognitive perceptual SNS scores decreased over time for both outcome groups; yet the 
non-response continued to have worse cognitive perceptual SNS scores. Furthermore, this 
reducation did not significantly differentiate the responsive and non-responsive groups, 
except for the week 8 assessments within the year one response group. Treatment 
responsive groups at week 26 and year 1 showed greater longitudinal within subject 
correlations between cognitive perceptual and symptoms, cognition, and functioning than 
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the non-responsive group. Repetitive motor was not as predicative or strongly correlated 
to clinical measures as cognitive perceptual SNS.  
The group differences reported here are consistent with past literature, which has 
reported that compared to HC and FEP-NSZ, FEP-SZ patients tend to have higher SNS 
scores with cognitive perceptual scores being markedly worse (Keshavan et al., 2003; 
Bachmann et al., 2014). While our findings parallel Keshavan’s earlier work, this study 
includes a larger sample size, explores the relationships between SNS and clinical 
variables, and evaluated relationships with respect to treatment response.  Over time, 
SNS scores tend to decrease for the FEP diagnostic groups and remain impaired 
compared to controls, while they remain relatively stable for HCs, which is also 
consistent with previous literature (Martins et al., 2008).  Additionally, the associations 
between SNS and symptomology, predominantly negative symptoms, are consistent with 
previous literature, which has shown that SNS scores parallel negative symptoms (Chan 
et al., 2015). No studies have evaluated SNS scores with respect to treatment 
responsiveness. However, studies examining the effect of antipsychotics on SNS scores 
have shown that patients on antipsychotic typically display a reduction in SNS scores, 
which is consistent with our results.  While there were no significant baseline cognitive 
perceptual differences, there were enhanced relationships between cognitive perceptual 
and symptomology, as well as cognition and functioning within treatment responsive 
groups.  
Compared to HCs, SZ patients tend to have a slower drop in SNS scores from 
adolescence to adulthood (Martins et al., 2008) and awareness of the SNS trajectory 
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course in addition to other diagnostic criteria can help physicians make earlier SZ 
diagnoses and thereby improve prognosis. Since an extended duration of untreated illness 
is generally associated with a worse prognosis (Loebel et al., 1992), earlier recognition of 
these signs can lead to earlier diagnosis and earlier exposure to preventative measures.  
While our findings did not show significant relationships between SNS and DUI, we 
found that cognitive perceptual was a better predictor of treatment outcome.  
Furthermore, since the presence of positive and negative symptoms is a prominent feature 
of schizophrenia, the association between SNS and symptomology can possibly 
contribute to the cognitive deficits SZ patients’ experience.  Moreover, previous literature 
has shown that SNS decreases with remission of symptomology (Bachmann et al., 2014).  
Therefore since SNS changes seem to parallel symptomology, the utilization of the 
change in SNS scores can help determine if a patient will or will not be responsive to 
treatment at week 26 and year 1.  Additionally, since the literature has shown mixed 
results for prolonged antipsychotic usage (Cuesta et al., 2012) evaluation of the change in 
SNS scores can potentially be an additionally factor help physician mediate antipsychotic 
usage. 
There are a number of significant advantages of this study evaluating SNS 
without the confounding influences of chronicity or previous neuroleptic usage. 
Additionally, by determining the effects of SNS over time, longitudinal studies allow for 
establishment of causality when compared to cross sectional studies. Furthermore, to our 
knowledge, this is the largest sample size of a single site longitudinal study reporting 
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SNS scores.  There are some limitations to this study, including patient attrition, lack of 
antipsychotic usage information, and missing data.  
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APPENDIX 
 
SUPPLEMENTAL	TABLE	1:	Logistic	Regression	for	Group	Comparisons	Note:	Data	was	co-varied	for	age,	sex,	race,	and	handedness.	(FEP-SZ=	First	Episode	Schizophrenia,	FEP-NSZ=	First	Episode	Non-Schizophrenia,	HC=	Healthy	Controls)	
GROUP	 Measures		 Estimate	 Std.Error	 zval	 pval	 Odds	
Ratio	
CI	
lower	
CI	
upper	
FEP_SZ-
HC	
COGNITIVE 
PERCEPTUAL  
2.859	 0.402	 7.109	 <0.001	 17.443	 7.930	 38.367	
	 REPETITIVE 
MOTOR  
1.913	 0.371	 5.158	 <0.001	 6.774	 3.274	 14.015	
FEP_NSZ-
HC	
COGNITIVE 
PERCEPTUAL  
2.101	 0.506	 4.156	 <0.001	 8.177	 3.036	 22.026	
	 REPETITIVE 
MOTOR 
1.202	 0.422	 2.848	 0.004	 3.327	 1.455	 7.611	
FEP_SZ-
FEP_NSZ	
COGNITIVE 
PERCEPTUAL  
0.977	 0.361	 2.709	 0.007	 2.657	 1.310	 5.387	
	 REPETITIVE 
MOTOR  
0.540	 0.349	 1.548	 0.122	 1.716	 0.866	 3.400	
	 DURATION 
OF ILLNESS 
<0.001	 0.001	 -0.21	 0.838	 1.000	 0.999	 1.001	
 
 
SUPLEMENTAL	TABLE	2:	Logistic	Regression	for	Treatment	Response	v	Non-Response	at	Week	26	and	Year	1.	Note:	Data	was	co-varied	for	age,	sex,	race,	and	handedness.	DUI=	Duration	of	Untreated	Illness)	
GROUP	 Measures	 Estimate	 Std	Error	 zval	 pval	 Odds	
Ratio	
CI	
lower	
CI	upper	
Response	
to	Non-
Response	
at	Week	
26	
COGNITIVE	
PERCEPTUAL		
0.966	 0.512	 1.9	 0.059	 2.628	 0.963	 7.170	
	 REPETITIVE	
MOTOR		
-0.949	 0.496	 -1.9	 0.056	 0.387	 0.146	 1.023	
	 WEEK	26	
CHANGE	IN	
COGNITIVE	
PERCEPTUAL	
1.497	 0.512	 2.9	 0.003	 4.466	 1.637	 12.189	
	 WEEK	26	
CHANGE	IN	
REPETITIVE	
-0.622	 0.474	 -1.3	 0.190	 0.537	 0.212	 1.360	
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MOTOR	
	 DUI	 0.002	 0.001	 2.2	 0.025	 1.002	 1.000	 1.004	
Response	
to	Non-
Response	
at	Year	1	
COGNITIVE	
PERCEPTUAL		
1.038	 0.945	 1.1	 0.272	 2.824	 0.443	 18.008	
	 REPETITIVE	
MOTOR		
-1.655	 0.740	 -2.2	 0.025	 0.191	 0.045	 0.815	
	 WEEK	26	
CHANGE	IN	
COGNITIVE	
PERCEPTUAL		
1.521	 0.688	 2.21	 0.027	 4.578	 1.188	 17.636	
	 WEEK	26	
CHANGE	IN	
REPETITIVE	
MOTOR	
-0.731	 0.734	 -1.0	 0.319	 0.481	 0.114	 2.027	
	 YEAR	1	
CHANGE	IN	
COGNITIVE	
PERCEPTUAL		
-0.095	 0.838	 -0.1	 0.910	 0.910	 0.176	 4.702	
	 YEAR	ONE	
CHANGE	IN	
REPETITIVE	
MOTOR		
-0.908	 0.713	 -1.3	 0.203	 0.403	 0.100	 1.632	
	 DUI	 0.001	 0.001	 1.16	 0.247	 1.001	 0.999	 1.003	
 	
SUPPLEMENTAL TABLE 3: Means of SNS measures across proband and HC groups 
at baseline, week 4, week 8, week 26, year 1, year 2, and year 4. (FEP-NSZ= first episode 
psychosis non-schizophrenia, FEP-SZ= first episode schizophrenia, HC=healthy controls) 
 SNS Measure  Groups p value 
Baseli
ne  
 FEP-
NSZ 
(n=76) 
FEP-SZ 
(n=236) 
HC 
(n=169
) 
FEP-
NSZ-
HC 
FEP-
SZ-HC 
FEP-
NSZ-
FEP-
SZ 
 Cognitive Perceptual Mean 
(sd)* 
0.38 
(0.4) 
0.628 
(0.5) 
0.173 
(0.3) 
<0.001 <0.001 <0.001 
 Repetitive Motor Mean 
(sd)* 
0.43 
(0.4) 
0.557 
(0.5) 
0.23 
(0.3) 
0.001 <0.001 0.030 
WEE
K 4 
 FEP-
NSZ 
(n=27) 
FEP-SZ 
(n=94) 
HC 
(n=2) 
   
 Cognitive Perceptual Mean 
(sd) 
0.20 
(0.3) 
0.42 
(0.5) 
0.33 
(0.5) 
0.810 0.810 0.070 
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 Repetitive Motor Mean 
(sd) 
0.32 
(0.4) 
0.53 
(0.5) 
0.13 
(0.2) 
0.672 0.354 0.052 
WEE
K 8 
 FEP-
NSZ 
(n=28) 
FEP-SZ 
(n=64) 
HC 
(n=65) 
   
 Cognitive Perceptual Mean 
(sd)* 
0.37 
(0.4) 
0.41 
(0.5) 
0.12 
(0.3) 
0.003 <0.001 0.831 
 Repetitive Motor Mean 
(sd)* 
0.28 
(0.3) 
0.30 
(0.3) 
0.15 
(0.3) 
0.151 0.030 0.681 
WEE
K 26 
 FEP-
NSZ 
(n=48) 
FEP-SZ 
(n=138) 
HC 
(n=66) 
   
 Cognitive Perceptual Mean 
(sd)* 
0.18 
(0.3) 
0.41 
(0.4) 
0.136 
(0.3) 
0.347 <0.001 0.004 
 Repetitive Motor Mean 
(sd)* 
0.30 
(0.4) 
0.44 
(0.4) 
0.117 
(0.2) 
0.017 <0.001 0.017 
YEA
R 1 
 FEP-
NSZ 
(n=43) 
FEP-SZ  
(n=127) 
HC 
(n=127) 
   
 Cognitive Perceptual Mean 
(sd)* 
0.14 
(0.2) 
0.25 
(0.3) 
0.08 
(0.2) 
0.078 <0.001 0.078 
 Repetitive Motor Mean 
(sd)* 
0.31 
(0.4) 
0.43 
(0.4) 
0.20 
(0.3) 
0.095 0.000 0.095 
YEA
R 2 
 FEP_NS
Z 
(n=14) 
FEP_S
Z 
(n=54) 
HC 
(n=36) 
   
 Cognitive Perceptual Mean 
(sd)* 
0.14 
(0.3) 
0.37 
(0.4) 
0.13 
(0.2) 
0.616 0.016 0.191 
 Repetitive Motor Mean 
(sd)* 
0.25 
(0.3) 
0.59 
(0.6) 
0.19 
(0.3) 
0.404 0.002 0.140 
YEA
R 4 
 FEP_NS
Z 
(n=8) 
FEP_S
Z 
(n=32) 
HC 
(n=14) 
   
 Cognitive Perceptual Mean 
(sd) 
0.29 
(0.4) 
0.46 
(0.4) 
0.214 
(0.3) 
0.489 0.175 0.489 
 Repetitive Motor Mean 
(sd)* 
1.06 
(0.7) 
0.61 
(0.6) 
0.143 
(0.234) 
0.002 0.010 0.102 			
SUPPLEMENTAL TABLE 4: Mean differences of SNS measures between week 26 
non-response and response at baseline, week 4, week 8, and week 26. (SE=standard 
error) 
TIMEPT	 Week	26	
Treatment	
Group	
N	 SNS	Measure	 Mean	(sd)	 SE	 P	
value		
	 	 	 	 	 	 	
	40 
Baseline	 Non-Response	 10
5	
Cognitive	
Perceptual		
0.565(0.5)	 0.052	 0.587	
	 Response		 10
5	
	 0.567(0.5)	 0.050	 	
	 Non-Response	 10
5	
Repetitive	
Motor		
0.517(0.4)	 0.042	 0.063	
	 Response		 10
5	
	 0.590(0.5)	 0.048	 	
Week	4	 Non-Response		 40	 Cognitive	
Perceptual	
0.435(0.5)	 0.079	 0.285	
	 Response		 64	 	 0.339(0.4)	 0.053	 	
	 Non-Response	 39	 Repetitive	
Motor		
0.451(0.4)	 0.067	 0.990	
	 Response		 64	 	 0.531(0.5)	 0.062	 	
Week	8	 Non-Response		 43	 Cognitive	
Perceptual		
0.457(0.5)	 0.069	 0.209	
	 Response		 24	 	 0.264(0.4)	 0.085	 	
	 Non-Response	 43	 Repetitive	
Motor		
0.233(0.3)	 0.038	 0.038	
	 Response		 34	 	 0.396(0.4)	 0.075	 	
Week	26	 Non-Response		 92	 Cognitive	
Perceptual		
0.417(0.5)	 0.047	 0.066	
	 Response		 93	 	 0.272(0.3)	 0.035	 	
	 Non-Response	 92	 Repetitive	
Motor		
0.351(0.4)	 0.038	 0.227	
	 Response		 93	 	 0.447(0.5)	 0.048	 	
 
SUPPLEMENTAL TABLE 5: Differences of SNS measures between year 1 non-
response and response at baseline, week 4, week 8, week 26, and year 1. (SE=standard 
error) 
Time	Point		 Year	1	Treatment	
						Group	
N	 SNS	Measure	 Mean	(sd)	 SE	 p	
value	
Baseline	 Non-Response	 97	 Cognitive	
Perceptual	
0.506(0.5)	 0.052	 0.649	
	 Response	 10
1	
	 0.548(0.5)	 0.048	 	
	 Non-Response	 97	 Repetitive	Motor	 0.491(0.4)	 0.042	 0.04	
	 Response	 10
1	
	 0.588(0.5)	 0.517	 	
Week	4	 Non-Response	 39	 Cognitive	
Perceptual	
0.436(0.5)	 0.08	 0.599	
	 Response	 57	 	 0.327(0.4)	 0.048	 	
	41 
	 Non-Response	 38	 Repetitive	Motor	 0.421(0.4)	 0.065	 0.513	
	 Response	 57	 	 0.496(0.5)	 0.063	 	
Week	8	 Non-Response	 35	 Cognitive	
Perceptual	
0.495(0.5)	 0.08	 0.024	
	 Response	 30	 	 0.156(0.2)	 0.044	 	
	 Non-Response	 35	 Repetitive	Motor	 0.286(0.3)	 0.056	 0.636	
	 Response	 30	 	 0.3(.3)	 0.05	 	
Week	26	 Non-Response	 72	 Cognitive	
Perceptual	
0.403(0.4)	 0.05	 0.267	
	 Response	 77	 	 0.273(0.4)	 0.04	 	
	 Non-Response	 72	 Repetitive	Motor	 0.319(.3)	 0.041	 0.049	
	 Response	 77	 	 0.467(.5)	 0.056	 	
Year	1	 Non-Response	 79	 Cognitive	
Perceptual	
0.249(0.3)	 0.035	 0.815	
	 Response	 90	 	 0.196(0.3)	 0.031	 	
	 Non-Response	 79	 Repetitive	Motor	 0.351(0.4)	 0.044	 0.120	
	 Response	 90	 	 0.436(0.4)	 0.045	 	
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